Patients with a particular kind of advanced lung cancer have shown a significant extension in their lives using a new combination therapy that combines chemotherapy and AstraZeneca‘s popular medicine Tagrisso (osimertinib). At the IASLC 2025 World Conference on Lung Cancer, the FLAURA2 Phase III trial’s final results were presented. They showed that the combination therapy had the longest median overall survival for patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) ever recorded in a global Phase III trial, at almost four years.
According to the study, the median overall survival for patients treated with Tagrisso + chemotherapy was 47.5 months, which was significantly longer than the 37.6 months for individuals treated with Tagrisso alone. For patients receiving the combo medication, this translates into a 23% lower chance of mortality. Additionally, the data revealed that, at the four-year mark, 40.8% of patients on Tagrisso alone were still alive, whereas 49.1% of patients on the combo medication were still alive.
Read More: AstraZeneca’s Datroway Receives US Approval for EGFR-Mutated Lung Cancer
Summary of OS results: FLAURA2
| Metric | Tagrisso plus chemotherapy (n=279) | Tagrisso monotherapy (n=278) |
| Median OS (in months) | 47.5 (41.0-NC) | 37.6 (33.2, 43.2) |
| Hazard ratio (95% CI) | 0.77 (0.61-0.96) | |
| Stratified log-rank p-value | 0.0202 | |
| Number of deaths, n (%) | 144 (51.6) | 171 (61.5) |
| Data maturity | 57% | |
| OS rate at 24 months (%) | 79.7 (74.5-84.0) | 71.5 (65.8-76.5) |
| OS rate at 36 months (%) | 63.1 (57.1-68.5) | 50.9 (44.8-56.6) |
| OS rate at 48 months (%) | 49.1 (43.0-55.0) | 40.8 (34.9-46.6) |
The latest FLAURA2 trial results set a new survival standard for patients, with Tagrisso plus chemotherapy demonstrating a median overall survival of nearly four years in 1st-line advanced EGFR-mutated lung cancer—surpassing the three-year benchmark established in the FLAURA trial. Over the past decade, Tagrisso has consistently delivered strong survival benefits and tolerable safety across all stages of non-small cell lung cancer, cementing its role as the backbone therapy in EGFR-mutated lung cancer.
Susan Galbraith
Read More: AstraZeneca’s Gefurulimab Shows Major Promise in Late-Stage Myasthenia Gravis Trial
It was discovered that the combination therapy’s safety profile was controllable and in line with the known adverse effects of the separate medications. Even while a greater proportion of patients receiving the combo therapy had serious side effects, these were mostly caused by the well-known side effects of chemotherapy.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
The FLAURA2 trial’s findings have the potential to revolutionize the way that patients with EGFR-mutated NSCLC are treated by presenting a novel, highly successful treatment option that can greatly increase survival and give patients and their families fresh hope.
Last Modified:
Graduated from the University of Kerala'20 with B.Sc. Botany & Biotechnology. Post-graduation in Biotechnology from the University of Kerala'22. Internship experience in Cancer Research.
